Literature DB >> 28355425

Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.

Laura Sowerby1, Anna K Dewan1, Scott Granter2, Leena Gandhi3, Nicole R LeBoeuf1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28355425     DOI： 10.1001/jamadermatol.2017.0091

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  28 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 2.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

3.  Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.

Authors:  Hajir Ibraheim; Esperanza Perucha; Nick Powell
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

4.  Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients.

Authors:  Jonathan J Lo; Meghan M Heberton; Omar Pacha; Auris O Huen; Anisha B Patel
Journal:  Support Care Cancer       Date:  2021-09-14       Impact factor: 3.603

Review 5.  Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.

Authors:  Benjamin C Park; Seungyeon Jung; Steven T Chen; Anna K Dewan; Douglas B Johnson
Journal:  Am J Clin Dermatol       Date:  2022-06-16       Impact factor: 6.233

6.  Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.

Authors:  Pradnya D Patil; Anthony P Fernandez; Vamsidhar Velcheti; Ahmad Tarhini; Pauline Funchain; Brian Rini; Mohamad Khasawneh; Nathan A Pennell
Journal:  Oncologist       Date:  2018-10-24

Review 7.  Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

Authors:  Jennifer Choi; Ronald Anderson; Ada Blidner; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas Johnson; Vickie R Shannon; Maria Suarez-Almazor; Bernardo L Rapoport; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2020-08-27       Impact factor: 3.603

Review 8.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

Review 9.  Immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-23       Impact factor: 11.527

10.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Authors:  Gregory S Phillips; Jennifer Wu; Matthew D Hellmann; Michael A Postow; Naiyer A Rizvi; Azael Freites-Martinez; Donald Chan; Stephen Dusza; Robert J Motzer; Jonathan E Rosenberg; Margaret K Callahan; Paul B Chapman; Larisa Geskin; Adriana T Lopez; Vanessa A Reed; Gabriella Fabbrocini; Maria Carmela Annunziata; Oluwaseun Kukoyi; Aliyah Pabani; Chih-Hsun Yang; Wen-Hung Chung; Alina Markova; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2019-06-19       Impact factor: 50.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.